The New Genentech

anonymous

Guest
I've been reading the numerous posts about the new MS franchise, future sales positions and the interview/hiring process for these positions. Clearly there is mixed impressions about how it is going, what life is like working here and how the company is today compared to prior to the Roche merger.
To all veteran Genentech peeps, this isn't the company it was 10 years ago. Art Levinson isn't coming to the next town hall meeting to hear about your grievances. This company is now working in competitive markets where you actually need to sell, not just show up with a smile and a new patient education booklet. Lytics is the only franchise without competition. Every company in oncology has their sights on dethroning Genentech at every opportunity they can. We all have sales goals but unless you really suck or tell your manager they are worthless, you most likely are not at risk of getting canned here. This company is too concerned about ever having a corporate integrity agreement and OIG investigation levied against it and won't hold your feet to the fire to deliver the numbers as did GSK, BMS and countless others who've pushed the envelop and who now have a wall of shame in the executive office.

To all outside reps looking to join in, it is a hard company to get into (I tried several times a decade ago before finally landing a spot). Everyone looking to join here has to be honest with themselves about the pros and cons of where you currently work and then you have to do a due diligence of the pros and cons of working here. Speak with existing clinical specialists whenever you can, don't use this forum to figure out how to get onboard. It may or may not be a fit for you and if you didn't make it through the process, being bitter on here may make you feel good, but you either weren't the best fit for the position or you just just didn't take it serious. There have been over 5000 applicants for MS, with 160 spots, you are not ensured anything

This company has its lumps and bumps, warts and moles as do ALL other similar sized pharma companies. If you want the Genentech of old, good luck landing at a one product start up that allows you to do what you want/need to in order to get the business. They don't stay independent long before the Pfizers' and Novartis' scoop them up and then you're back under big pharma. The grass is green wherever you go, just a different shade.

Genentech has by far the best benefit package of any company when you factor in all that is laid out on the table. Unless you're financially set for life and can thumb your nose at this, it is hard to ignore this side of the compensation.

Bitch and moan all you want about this company, it isn't what it once was, but then again, what company in what industry is?

Thank you for reading, make it a great day.
 






Well stated as the gravy train is losing steam and gravy...

The biosimilar threats to the DNA's profit engine 3 horsemen Rituxan/Herception/Avastin are REAL and around the corner in 2018. DNA is about to take pages out of Amgen and even Biogen playbook ofnRIF. Amgen shed 20% plus year or so before biosimilars came out on their Epo franchise and Biogen had gall to announce 10% plus RIF last Nov on their best quarter ever.

There was rumour of RIF at the end of 2015 and the rumour resurfaced recently with key management departures across the board in just about every function now that 2015 bonus are paid. These honchos are leaving 'cos they know what's coming ahead from Basel. Danny O'Day is well known for his financial shrewdness and after almost 3 yrs having taken over from uncle Pascal he is ready with sharpened meat cleavers and freshly finished wood chopping block.

It took me 3 yrs to get in myself and immensely enjoyed the gravy train ride. Roche stock option was cream on top but alas all options since 2014 are pretty much worthless.

PS - watched PBS Nova on Alzheimer last night in SF bay area and it was nice to see a lot of coverage on DNA scientists and smidgeon on Lilly and Biogen (why no Pfizer?). That said both DNA's Crenezumab and Roche's Ganterumab were NOT developed by DNA G-Red but acquired from outside...
 






Well stated as the gravy train is losing steam and gravy...

The biosimilar threats to the DNA's profit engine 3 horsemen Rituxan/Herception/Avastin are REAL and around the corner in 2018. DNA is about to take pages out of Amgen and even Biogen playbook ofnRIF. Amgen shed 20% plus year or so before biosimilars came out on their Epo franchise and Biogen had gall to announce 10% plus RIF last Nov on their best quarter ever.

There was rumour of RIF at the end of 2015 and the rumour resurfaced recently with key management departures across the board in just about every function now that 2015 bonus are paid. These honchos are leaving 'cos they know what's coming ahead from Basel. Danny O'Day is well known for his financial shrewdness and after almost 3 yrs having taken over from uncle Pascal he is ready with sharpened meat cleavers and freshly finished wood chopping block.

It took me 3 yrs to get in myself and immensely enjoyed the gravy train ride. Roche stock option was cream on top but alas all options since 2014 are pretty much worthless.

PS - watched PBS Nova on Alzheimer last night in SF bay area and it was nice to see a lot of coverage on DNA scientists and smidgeon on Lilly and Biogen (why no Pfizer?). That said both DNA's Crenezumab and Roche's Ganterumab were NOT developed by DNA G-Red but acquired from outside...

Retina had a small RIF in January. Of course he new term is optimization of field force. If you were shown the door, you were optimized
 












Retina had a small RIF in January. Of course he new term is optimization of field force. If you were shown the door, you were optimized

Well we've seen this movie before with big pharmas 8-10 yrs ago and likes of Pfizer which literally mowed down the sales force. I'm afraid it's coming to even DNA and thus the reason so many insiders got on the MS bandwagon on the annual development plan and openings in their territories as DNA will add a lot of people on new non-oncology molecule and not slash like the recent Lucentis franchise RIF which had been under a lot of pressure due to the better drug from Regeneron Eylea and especially hell of lot cheaper diluted Lucentis.
 






Thank you for posting this.

Very well said.

Thanks. I think it is a pretty fair perspective on the company we work for. Either be thankful you're here and have the benefits we do or keep chasing the dream. Another democrat in the White House could really put pharma in the cross hairs and then who knows how leadership of all companies respond.
I hate to say it but some day, MSLs will be the field sales org even if they aren't aligned with sales.